PL1629004T3 - Kompozycje immunogenne obejmujące wektory oparte na replikonie wirusa wenezuelskiego końskiego zapalenia mózgu i antygeny białka paramyksowirusa - Google Patents
Kompozycje immunogenne obejmujące wektory oparte na replikonie wirusa wenezuelskiego końskiego zapalenia mózgu i antygeny białka paramyksowirusaInfo
- Publication number
- PL1629004T3 PL1629004T3 PL04776196T PL04776196T PL1629004T3 PL 1629004 T3 PL1629004 T3 PL 1629004T3 PL 04776196 T PL04776196 T PL 04776196T PL 04776196 T PL04776196 T PL 04776196T PL 1629004 T3 PL1629004 T3 PL 1629004T3
- Authority
- PL
- Poland
- Prior art keywords
- blebs
- immunogenic compositions
- equine encephalitis
- encephalitis virus
- venezuelan equine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47613703P | 2003-06-05 | 2003-06-05 | |
| PCT/US2004/017127 WO2005016961A1 (en) | 2003-06-05 | 2004-06-02 | Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens |
| EP04776196A EP1629004B1 (en) | 2003-06-05 | 2004-06-02 | Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1629004T3 true PL1629004T3 (pl) | 2009-02-27 |
Family
ID=34193021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04776196T PL1629004T3 (pl) | 2003-06-05 | 2004-06-02 | Kompozycje immunogenne obejmujące wektory oparte na replikonie wirusa wenezuelskiego końskiego zapalenia mózgu i antygeny białka paramyksowirusa |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7541038B2 (pl) |
| EP (1) | EP1629004B1 (pl) |
| JP (1) | JP2007534295A (pl) |
| KR (1) | KR20060017635A (pl) |
| CN (1) | CN1798760A (pl) |
| AT (1) | ATE404582T1 (pl) |
| AU (1) | AU2004265232A1 (pl) |
| BR (1) | BRPI0411099A (pl) |
| CA (1) | CA2526146A1 (pl) |
| DE (1) | DE602004015775D1 (pl) |
| DK (1) | DK1629004T3 (pl) |
| ES (1) | ES2311857T3 (pl) |
| MX (1) | MXPA05012542A (pl) |
| PL (1) | PL1629004T3 (pl) |
| PT (1) | PT1629004E (pl) |
| SI (1) | SI1629004T1 (pl) |
| WO (1) | WO2005016961A1 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI377253B (en) | 2001-04-16 | 2012-11-21 | Martek Biosciences Corp | Product and process for transformation of thraustochytriales microorganisms |
| WO2003101484A1 (en) * | 2002-05-31 | 2003-12-11 | Thomas Jefferson University | Compositions and methods for transepithelial molecular transport |
| WO2006078294A2 (en) * | 2004-05-21 | 2006-07-27 | Novartis Vaccines And Diagnostics Inc. | Alphavirus vectors for respiratory pathogen vaccines |
| EP2205751A2 (en) * | 2007-09-26 | 2010-07-14 | Vanderbilt University | Vaccine for rsv and mpv |
| ES2752196T3 (es) | 2009-03-16 | 2020-04-03 | Dsm Ip Assets Bv | Producción de proteínas en microorganismos del filo Labyrinthulomycota |
| US8540358B2 (en) * | 2009-08-10 | 2013-09-24 | Kornit Digital Ltd. | Inkjet compositions and processes for stretchable substrates |
| EP3505632B1 (en) * | 2009-12-28 | 2022-08-03 | Sanofi Vaccine Technologies, S.A.S. | Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof |
| IN2012DN06278A (pl) * | 2009-12-28 | 2015-09-25 | Dsm Ip Assets Bv | |
| SG11201404711WA (en) * | 2012-02-16 | 2014-09-26 | Vlp Therapeutics Llc | Virus like particle composition |
| CA3062591A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
| US20200362313A1 (en) * | 2017-09-13 | 2020-11-19 | Biontech Rna Pharmaceuticals Gmbh | Method of enhancing rna expression in a cell |
| EP3735271A4 (en) | 2018-01-04 | 2022-06-15 | Iconic Therapeutics, Inc. | ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS |
| JP7457733B2 (ja) | 2019-05-30 | 2024-03-28 | グリットストーン バイオ インコーポレイテッド | 改変アデノウイルス |
| WO2021138447A1 (en) | 2019-12-31 | 2021-07-08 | Elixirgen Therapeutics, Inc. | Temperature-based transient delivery of nucleic acids and proteins to cells and tissues |
| WO2022032196A2 (en) | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
| CN114317563B (zh) * | 2021-12-17 | 2023-09-05 | 华南理工大学 | 提高基因表达的rna复制子及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| ATE105334T1 (de) * | 1988-04-22 | 1994-05-15 | Upjohn Co | Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3. |
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US5185440A (en) | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
| US5580564A (en) | 1990-08-15 | 1996-12-03 | Akzo Nobel N.V. | Method for modifying the cell, tissue or host tropism of microorganisms; recombinant microorganisms obtained in this way and use thereof in medicine and veterinary medicine |
| US5512421A (en) | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| WO1999025858A1 (en) * | 1997-11-14 | 1999-05-27 | Connaught Laboratories Limited | Alphavirus vectors for paramyxovirus vaccines |
| WO1999032648A1 (en) | 1997-12-22 | 1999-07-01 | The University Of Tennessee Research Corporation | Recombinant rhabdovirus containing a heterologous fusion protein |
| EP1255849A2 (en) | 2000-01-28 | 2002-11-13 | Thomas Jefferson University | Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses |
| AU2001264824A1 (en) | 2000-06-01 | 2001-12-11 | St. Jude Children's Research Hospital | Vaccine and gene therapy vector and methods of use thereof |
| US20020187543A1 (en) | 2001-04-05 | 2002-12-12 | Curiel David T. | Enhanced dispersion of adenoviral vectors by fusogenic membrane glycoproteins |
| WO2002089728A2 (en) | 2001-04-20 | 2002-11-14 | Thomas Jefferson University | Recombinant rhabdoviruses as live-viral vaccines |
| US20030077251A1 (en) | 2001-05-23 | 2003-04-24 | Nicolas Escriou | Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins |
| WO2002099035A2 (en) * | 2001-05-31 | 2002-12-12 | Chiron Corporation | Chimeric alphavirus replicon particles |
| JP4991108B2 (ja) * | 2002-12-13 | 2012-08-01 | アルファバックス，インコーポレイティド | 多抗原性アルファウイルス・レプリコン粒子及び方法 |
-
2004
- 2004-06-02 KR KR1020057023359A patent/KR20060017635A/ko not_active Application Discontinuation
- 2004-06-02 US US10/559,429 patent/US7541038B2/en not_active Expired - Fee Related
- 2004-06-02 AU AU2004265232A patent/AU2004265232A1/en not_active Abandoned
- 2004-06-02 MX MXPA05012542A patent/MXPA05012542A/es active IP Right Grant
- 2004-06-02 CA CA002526146A patent/CA2526146A1/en not_active Abandoned
- 2004-06-02 PL PL04776196T patent/PL1629004T3/pl unknown
- 2004-06-02 PT PT04776196T patent/PT1629004E/pt unknown
- 2004-06-02 ES ES04776196T patent/ES2311857T3/es not_active Expired - Lifetime
- 2004-06-02 BR BRPI0411099-4A patent/BRPI0411099A/pt not_active IP Right Cessation
- 2004-06-02 CN CNA2004800150075A patent/CN1798760A/zh active Pending
- 2004-06-02 WO PCT/US2004/017127 patent/WO2005016961A1/en active Application Filing
- 2004-06-02 JP JP2006515041A patent/JP2007534295A/ja active Pending
- 2004-06-02 EP EP04776196A patent/EP1629004B1/en not_active Expired - Lifetime
- 2004-06-02 DE DE602004015775T patent/DE602004015775D1/de not_active Expired - Fee Related
- 2004-06-02 SI SI200430895T patent/SI1629004T1/sl unknown
- 2004-06-02 DK DK04776196T patent/DK1629004T3/da active
- 2004-06-02 AT AT04776196T patent/ATE404582T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US7541038B2 (en) | 2009-06-02 |
| DE602004015775D1 (de) | 2008-09-25 |
| AU2004265232A1 (en) | 2005-02-24 |
| US20070128222A1 (en) | 2007-06-07 |
| SI1629004T1 (sl) | 2008-12-31 |
| MXPA05012542A (es) | 2006-02-08 |
| BRPI0411099A (pt) | 2006-07-18 |
| JP2007534295A (ja) | 2007-11-29 |
| PT1629004E (pt) | 2008-11-14 |
| EP1629004B1 (en) | 2008-08-13 |
| ATE404582T1 (de) | 2008-08-15 |
| CA2526146A1 (en) | 2005-02-24 |
| CN1798760A (zh) | 2006-07-05 |
| DK1629004T3 (da) | 2008-11-17 |
| KR20060017635A (ko) | 2006-02-24 |
| ES2311857T3 (es) | 2009-02-16 |
| WO2005016961A1 (en) | 2005-02-24 |
| EP1629004A1 (en) | 2006-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1629004T3 (pl) | Kompozycje immunogenne obejmujące wektory oparte na replikonie wirusa wenezuelskiego końskiego zapalenia mózgu i antygeny białka paramyksowirusa | |
| EP1773403B1 (en) | Alphavirus-based adjuvants | |
| AR082427A2 (es) | Sistemas de expresion de virus parainfluenza recombinantes y vacunas que comprenden antigenos heterologos derivados de metapneumovirus | |
| EA200801756A1 (ru) | Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса | |
| Weger-Lucarelli et al. | A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice | |
| US20050266550A1 (en) | TC-83-derived alphavirus vectors, particles and methods | |
| Baldo et al. | Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination | |
| RU2011128371A (ru) | Модифицированные f протеины sv и способы их применения | |
| WO2004042001A3 (en) | Virus-like particles, methods of preparation, and immonogenic compositions | |
| US20120121650A1 (en) | Chimeric Virus Vaccines | |
| WO2001091536A3 (en) | Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens | |
| RU2008102654A (ru) | Инактивированные химерные вакцины и связанные с ними способы применения | |
| UY28867A1 (es) | Factor de permisividad celular para virus y usos del mismo | |
| WO2005115448A3 (en) | Multi plasmid system for the production of influenza virus | |
| WO2004004761A3 (en) | Adjuvant viral particle | |
| WO2007046839A3 (en) | New live virus vaccines | |
| WO2010008576A3 (en) | Idna vaccines and methods for using the same | |
| WO2003072725A3 (en) | Recombinant negative strand virus rna expression systems and vaccines | |
| CA2461579A1 (en) | Porcine adenovirus e1 region | |
| AU2018275790B2 (en) | Genetically attenuated nucleic acid vaccine | |
| DK1334197T3 (da) | Gær-afledt vaccine mod IPNV | |
| CA2495294A1 (en) | Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines | |
| WO2005026316A8 (en) | Alphavirus vaccines | |
| PT100460A (pt) | Partiiculas derivadas de virus de herpes e vacinas que as contem | |
| DE60335139D1 (de) | Virusähnliche partikel, verfahren zur herstellung und immunogene zusammensetzungen |